[go: up one dir, main page]

AU2012247530B2 - Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinocetan (FOLFIRI) - Google Patents

Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinocetan (FOLFIRI) Download PDF

Info

Publication number
AU2012247530B2
AU2012247530B2 AU2012247530A AU2012247530A AU2012247530B2 AU 2012247530 B2 AU2012247530 B2 AU 2012247530B2 AU 2012247530 A AU2012247530 A AU 2012247530A AU 2012247530 A AU2012247530 A AU 2012247530A AU 2012247530 B2 AU2012247530 B2 AU 2012247530B2
Authority
AU
Australia
Prior art keywords
aflibercept
dosage
patient
fluorouracil
irinotecan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012247530A
Other versions
AU2012247530A1 (en
Inventor
Remi Castan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46001286&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2012247530(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of AU2012247530A1 publication Critical patent/AU2012247530A1/en
Application granted granted Critical
Publication of AU2012247530B2 publication Critical patent/AU2012247530B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/178—Lectin superfamily, e.g. selectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Pharmaceutical composition comprising aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinocetan (FOLFIRI) useful in the treatment of Colorectal cancer (CRC).

Description

2012247530 03 Apr 2017 1
Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinotecan (FOLFIRI)
The present invention relates to combinations of aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinotecan which are therapeutically useful in the treatment of Colorectal Cancer (CRC) and in particular metastatic Colorectal Cancer (CRC).
Colorectal cancers are among the most frequent tumor types in the western countries, 5 second to breast in women and third to lung and prostate in males. The end prognosis is dependent upon the extent of the disease. The five year survival rate in early localized stage of about 90%, decreased to approximately 60-65% after spread to adjacent organ(s) or lymph nodes and is of less than 10% after spread to distant sites.
When diagnosed before nodal involvement treatment is usually limited to surgical 10 resection (and radiotherapy for patients with rectal cancer) and potential participation to clinical trials for adjuvant therapy. Patients with nodal involvement are candidates for adjuvant chemotherapy following initial surgery in the attempt to prevent metastatic recurrence of the disease. Once spread to distant sites treatment essentially consists of palliative chemotherapy. 15 About 75 to 80% of all the patients with colorectal carcinoma will present at a stage when all gross carcinoma can be surgically removed. However, almost half of these patients will ultimately die from metastatic disease. Furthermore 20 to 25 % of the patients present with metastatic disease at diagnosis. Once metastases are present median overall survival with available combination therapy is around 20 months. 20 Over the past decades 5-Fluorouracil (5-FU) has remained the mainstay of the chemotherapy in colorectal cancer. During years the major determinant in the treatment of colorectal cancer patients has been the improvement in the schedules of 5-FU administration.
Among these, the bimonthly regimen (LV5FU2) of 5-FU given as bolus/infusion over 2 25 days has been shown to be superior to the monthly 5 day bolus regimen (Mayo regimen) in terms of response rate (RR) (32.6% vs 14.4%), in terms of progression free survival (PFS) (27.6 vs 22.0 weeks), and safety (de Gramont et al, Journal of Clinical Oncology 1997;15(2):808-815). 2012247530 03 Apr 2017 2
However, no statistically significant improvement in the overall survival (OS) was seen until development, starting in the beginning of nineties, of two novel cytotoxic agents, oxaliplatin, a DACH platinum, and the topoisomerase I inhibitor, irinotecan. With each of these two new agents median overall survival in the first line metastatic setting 5 reached 15 to 19 months in multiple Phase III trials.
In a study, published in 2004 by Tournigand et al. (Journal of Clinical Oncology 2004;22(2):229-237), where these two drugs were administered in sequence in the same protocol, as first then second line treatment in metastatic colorectal cancer patients, the threshold of 20 months median overall survival was crossed whatever 10 was the order of the treatment sequence.
Aflibercept is synthesized as a fusion protein comprising the signal sequence of VEGFR1 fused to the D2 Ig domain of the VEGFR1 receptor, itself fused to the D3 Ig domain of the VEGFR2 receptor, in turn fused to the Fc domain of lgG1 Aflibercept is also referred to as as VEGFR1 R2-Fc.DELTA.C1 or Flt1D2.Flk1D3.Fc.DELTA.C1. 15 The amino acid sequence (SEQ ID N°1) of Aflibercept is illustrated in Figure 1 and is also shown inter alia in FIG. 24) of patent application WO 00/75319. 5-fluorouracil (5-FU or f5U) is a drug that is a pyrimidine analog which is used in the treatment of cancer. It is a suicide inhibitor and works through irreversible inhibition of thymidylate synthase. It belongs to the family of drugs called antimetabolites. 20 Folinic acid or leucovorin is an adjuvant to cancer chemotherapy used in combination with 5-fluorouracil.
Irinotecan is a drug used for the treatment of cancer. Irinotecan is a topoisomerase 1 inhibitor, which prevents DNA from unwinding. FOLFIRI is the combination of folinic acid, 5-fluorouracil (5-FU) and irinotecan and will 25 be used throughout the document.
In a phase I study (TCD6118) aflibercept was administered IV in combination with irinotecan (180 mg/m2 on day 1), leucovorin (200 mg/m2 on day 1 and day 2), and 5-FU (bolus/infusional 400/600 mg/m2 on day 1 and day 2), every 2 weeks in patients 2012247530 03 Apr 2017 3 with advanced solid malignancies. The aflibercept 4 mg/kg dose every 2 weeks was considered to be the optimum dose.
In a phase II trial (NCI7498) aflibercept was administered in previously treated patients with metastatic colorectal cancer. This trial showed that aflibercept is well 5 tolerated in pre-treated patients with MCRC. The conclusions are that based on the study results, studies of aflibercept as single agent or in combination should be explored (Tang et al, J Clin Oncol 26: 2008 (May 20 suppl; abstr 4027).
But the results provided in these two studies provided no insight as to efficacy.
Furthermore a phase III trial of aflibercept in metastatic pancreatic cancer was 10 discontinued in 2009 and in 2011 the data of a phase III trial evaluating aflibercept for the second-line treatment of non-small cell lung cancer (NSCLC) showed that adding aflibercept to the chemotherapy drug docetaxel did not meet the pre-specified criteria for the primary endpoint of improvement in overall survival compared with a regimen of docetaxel plus placebo. 15 It has now been found, and this is an object of the present invention, that the effectiveness of aflibercept on Overal Survival (OS) in patients with Colorectal Cancer (CRC) can be significantly improved when it is administered in combination with FOLFIRI.
It has also been found, and this is another object of the present invention, that the 20 effectiveness of aflibercept on Progression Free Survival (PFS) in patients with Colorectal Cancer (CRC) can be significantly improved when it is administered in combination with FOLFIRI.
It has also been found, and this is yet another object of the present invention, that the effectiveness of aflibercept on Overal Response Rate (ORR) in patients with 25 Colorectal Cancer (CRC) can be significantly improved when it is administered in combination with FOLFIRI.
The invention relates to methods, compositions and articles as disclosed herein.
In one aspect the invention provides for a method of treating Colorectal Cancer (CRC) or Colorectal Cancer (CRC) symptom in a patient in need thereof, said method 2012247530 03 Apr 2017 4 comprising administering to said patient therapeutically effective amounts of aflibercept and FOLFIRI. This method is safe and effective.
In a second aspect the invention provides for a method of increasing Overall Survival (OS) in a patient afflicted with CRC, said method comprising administering to said 5 patient therapeutically effective amounts of aflibercept and FOLFIRI.
In a third aspect the invention provides a method of increasing Overall Response Rate (ORR) in a patient afflicted with CRC, said method comprising administering to said patient therapeutically effective amounts of aflibercept and FOLFIRI.
In a fourth aspect the invention provides a method of increasing Progression Free 10 Survival (PFS) in a patient afflicted with CRC, said method comprising administering to said patient therapeutically effective amounts of aflibercept and FOLFIRI.
In a first feature the invention provides a method according to any one of the first to fourth aspects wherein said patient has already been treated for the CRC or CRC symptom (second-line treatment). 15 In a specific embodiment CRC is a Metastatic Colorectal Cancer.
In a second feature the invention provides for a method according to any one of the first to fourth aspects or the first feature wherein said patient has previously been treated with chemotherapy, radiotherapy or surgery. In an embodiment said patient has failed chemotherapy, radiotherapy or surgery. 20 In a third feature the invention provides a method according to any one of the first to fourth aspects or the first feature wherein said patient has previously been treated with therapy based on oxaliplatin or on bevacizumab.
In an embodiment said patient has failed therapy based on oxaliplatin or on bevacizumab. 25 In a fourth feature the invention provides a method wherein folinic acid at a dosage comprised between about 200 mg/m2 and about 600 mg/m2, 5-fluorouracil (5-FU) at a dosage comprised between about 2000 mg/m2 and about 4000 mg/m2, irinotecan at a dosage comprised between about 100 mg/m2 and about 300 mg/m2 and aflibercept at 2012247530 03 Apr 2017 5 a dosage comprised between about 1 mg/kg and about 10 mg/kg are administered to patient.
In the present application the dosage of folinic acid indicated should be understood as the dosage of the racemate of folinic acid, i.e. comprising the D and L forms. Should 5 only the L form be used the dosage should be half of the dosage indicated for the racemate.
In other words a dosage of folinic acid of about 200 mg/m2as indicated in the present application corresponds to about 200 mg/m2 of racemate and about 100 mg/m2 of L form. 10 In a fifth feature the invention provides a method wherein folinic acid at a dosage of about 400 mg/m2, 5-fluorouracil (5-FU) at a dosage of about 2800 mg/m2, irinotecan at a dosage of about 180 mg/m2 and aflibercept at a dosage of about 4 mg/kg are administered to patient.
In a sixth feature the invention provides a method wherein said patient receives 15 intravenous folinic acid at a dosage comprised of about 400 mg/m2, intravenous 5-fluorouracil (5-FU) at a dosage of about 2800 mg/m2, intravenous irinotecan at a dosage comprised of about 180 mg/m2 and intravenous aflibercept at a dosage of about 4 mg/kg every two weeks.
In a seventh feature the invention provides a method wherein said patient receives 20 intravenous folinic acid, intravenous 5-fluorouracil (5-FU), intravenous irinotecan and intravenous aflibercept every two weeks for a period comprised between about 9 and about 18 weeks.
In another feature the invention provides a method wherein said patient receives intravenous folinic acid immediately after aflibercept administration. 25 In another feature the invention provides a method wherein said patient receives intravenous irinotecan immediately after aflibercept administration.
In another feature the invention provides a method wherein said patient receives intravenous irinotecan immediately after aflibercept administration over almost 90 minutes. 6 2012247530 03 Apr 2017
In another feature the invention provides a method wherein said patient receives intravenous 5-fluorouracil (5-FU) immediately after aflibercept administration.
In another feature the invention provides a method wherein said patient receives a first quantity of intravenous 5-fluorouracil (5-FU) immediately after aflibercept 5 administration and a second quantity in continous infusion.
In another feature the invention provides a method wherein said patient receives about 400 mg/m2 of intravenous 5-fluorouracil (5-FU) over about 2 to 4 minutes after aflibercept administration and 2400 mg/m2 over about 46 hours after aflibercept administration in continuous infusion. 10 In a fifth aspect the invention features a composition comprising therapeutically effective amounts of aflibercept in combination with folinic acid, 5-fluorouracil (5-FU) and irinotecan for treating patients with CRC for simultaneous administration.
In a sixth aspect the invention features a composition comprising therapeutically effective amounts of aflibercept in combination with folinic acid, 5-fluorouracil (5-FU) 15 and irinotecan for treating patients with CRC for sequential administration.
In a seventh aspect the invention features a composition comprising therapeutically effective amounts of aflibercept in combination with folinic acid, 5-fluorouracil (5-FU) and irinotecan for treating patients with CRC for administration that is spaced out over a period of time so as to obtain the maximum efficacy of the combination. 20 In a eighth aspect the invention features a composition comprising therapeutically effective amounts of aflibercept in combination with folinic acid, 5-fluorouracil (5-FU) and irinotecan and comprising a pharmaceutically acceptable carrier for treating patients with CRC.
In on feature of any of these aspects the patient has liver metastases. 25 In an ninth aspect the invention features an article of manufacture comprising: a) a packaging material b) aflibercept, and c) a label or package insert contained within said packaging material indicating that aflibercept in combination with folinic acid, 5-fluorouracil (5-FU)
30 and irinotecan is effective for the treatment of CRC 7
In one feature of the ninth aspect the label or package insert contained within said packaging material indicates that aflibercept in combination with FOLFIRI improves Overall Survival (OS).
In one feature of the ninth aspect the label or package insert contained within said packaging material indicates that aflibercept in combination with FOLFIRI improves Progression Free Survival (PFS).
In one feature of the ninth aspect the label or package insert contained within said packaging material indicates that aflibercept in combination with FOLFIRI improves Overall Response Rate (ORR).
In a tenth aspect the invention features a kit for treating patients with CRC comprising: a) at least one compound chosen from the list consisting of aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinotecan; and b) a label or package insert contained within said kit indicating that aflibercept is to be used in combination with folinic acid, 5-fluorouracil (5-FU) and irinotecan (FOLFIRI) or folinic acid, 5-fluorouracil (5-FU) and irinotecan (FOLFIRI) is to be used in combination with Aflibercept
In an eleventh aspect the invention features a kit comprising in separate containers pharmaceutical compositions for combined use in treating CRC in a patient which comprises (1) a pharmaceutical composition comprising aflibercept, (2) a pharmaceutical composition comprising folinic acid, (3) a pharmaceutical composition comprising 5-fluorouracil (5-FU) and (4) a pharmaceutical composition comprising irinotecan.
The aflibercept can be formulated as described in W02006/104852. The man skilled in the art may refer in particular to W02006/104852 or to WO 00/75319 to carry out the present invention.
Comprises/comprising and grammatical variations thereof when used in this specification are to be taken to specify the presence of stated features, integers, steps or components or groups thereof, but do not preclude the presence or addition of one or more other features, integers, steps, components or groups thereof.
Figures
Figure 1: Aflibercept amino acid sequence (SEQ ID NO:1 ) 7a 2012247530 03 Apr 2017
Figure 2: Overall survival (months) - Kaplan-Meier curves by treatment group- ITT population 5 2012247530 03 Apr 2017 8
Figure 3 : Overall survival (months) - Subgroup analyses (forest plot) - By stratification factors as per IVRS - ITT population
Figure 4 : Overall survival (months) - Subgroup analyses (forest plot) - By patient demographics - ITT population 5 Figure 5 : Overall survival (months) - Subgroup analyses (forest plot) - By baseline characteristics - ITT population
Figure 6 : PFS based on tumor assessment by the IRC (months) - Subgroup analysis (forest plot) - By stratification factors as per IVRS - ITT population
The following example illustrates a combination according to the invention. 10 EFC10262 (VELOUR)/A Multinational. Randomized. Double-blind Study,
Comparing the Efficacy of Aflibercept Once Every 2 Weeks versus Placebo in Patients with Metastatic Colorectal Cancer (MCRC) Treated with Irinotecan / 5-FU Combination (FOLFIRI) after failure of an oxaliplatin based regimen EFC10262 was designed as a randomized, double-blind, multi-centre study 15 comparing aflibercept at 4 mg/kg to placebo, in combination with Irinotecan and 5 Fluorouracil combination (FOLFIRI) given intravenously every 2 weeks as second line treatment for patients with metastatic colorectal cancer (MCRC) after failure of an oxaliplatin based regimen. Each randomized patient was to be treated until disease progression, death, or unacceptable toxicity. 20 The primary objective of EFC10262 was to demonstrate improvement in overall survival (OS) for aflibercept + FOLFIRI compared to placebo + FOLFIRI. The predefined statistical significance level for this final analysis was 0.0466 after adjusting the type I error spent for the two interim analyses using the O’Brien-Fleming spending function. 25 The study included one formal interim analysis, planned for the purpose of efficacy, when 561 death events (65% information time) had occurred. Upon request of the independent Data Monitoring Committee (DMC), an additional interim analysis of OS was performed to provide an early evaluation of the benefit-risk ratio, when 315 death events (36.5% information fraction) had occurred. 9 2012247530 03 Apr 2017 A total of approximately 863 deaths were required to detect 20% hazard rate reduction in OS with 90% power using the two-sided log rank test at an overall 0.0499 alpha level. The median survival times was expected to be 11 months for the control group. The overall alpha level was split between overall survival (0.0499) and 5 progression-free survival as a secondary efficacy endpoint (0.0001).
Approximately 1200 patients (i.e. 600 patients per treatment group) were planned to be randomized. Treatment assignment was stratified according to prior therapy with bevacizumab (yes or no), and ECOG performance status (PS) (0 vs 1 vs 2).
The enrolment started in November 2007 and was completed in March 2010. A total 10 of 1226 patients were randomized. The efficacy analysis was based on all randomized patients (Intent-to-Treat (ITT) population: 614 in the placebo arm and 612 patients in the aflibercept arm). The safety analysis was based on all treated patients (safety population: 605 and 611 patients in the placebo and aflibercept arms, respectively).
Treatment arms were evenly balanced for demographics, disease characteristics and 15 prior anti-cancer treatments, including prior exposition to bevacizumab.
Dosage and schedule of administration
Patients were administered either aflibercept or placebo, depending on arm assigned. Immediately after, patients received irinotecan, 5-FU and leucovorin (FOLFIRI regimen). 20 This treatment was repeated every 2 weeks.
Aflibercept/placebo
Arm A, aflibercept: 4 mg/kg was administered IV over 1 hour on Day 1, every 2 weeks,
OR 25 Arm B, placebo: 4 mg/kg was administered IV over 1 hour on Day 1, every 2 weeks. FOLFIRI regimen
Immediately after aflibercept/placebo administration, all the patients received: - Irinotecan 180 mg/m2 IV infusion in 500 mL in 5% dextrose solution in water (D5W) over 90 minutes and dextro-levogyre (dl) leucovorin 400 mg/m2 IV 30 infusion over 2 hours, at the same time, in bags using a Y-line, followed by: 5-FU 400 mg/m2 IV bolus given over 2-4 minutes, followed by: 2012247530 03 Apr 2017 10 5-FU 2400 mg/m2 continuous IV infusion in 500 mL D5W (recommended) over 46-hours.
Results of EFC10262
Demographics and baseline characteristics 5 Patient demographics and characteristics at baseline were similar the 2 treatment arms (Table 1).
Table 1 - Summary of patient demographics and patient characteristics at baseline - ITT population
Placebo/Folfiri (N=614) Aflibercept/Folfiri (N=612) All (N=1226) Gender [n(%)] Number 614 612 1226 Male 353 (57.5%) 365 (59.6%) 718 (58.6%) Female 261 (42.5%) 247 (40.4%) 508 (41.4%) Age (Years) Number 614 612 1226 Median 61.0 61.0 61.0 Mean (SD) 60.2 (10.8) 59.5(10.5) 59.8(10.7) Min : Max CD CD CD 21 : 82 CD 00 CD Age class [n(%)] Number 614 612 1226 <65 376 (61.2%) 407 (66.5%) 783 (63.9%) >65 but <75 199 (32.4%) 172 (28.1%) 371 (30.3%) >75 39 (6.4%) 33 (5.4%) 72 (5.9%) Race [n(%)] Number 614 612 1226 Caucasian/White 523 (85.2%) 548 (89.5%) 1071 (87.4%) Black 27 (4.4%) 16 (2.6%) 43 (3.5%) Asian/Oriental 51 (8.3%) 35 (5.7%) 86 (7.0%) Other 13 (2.1%) 13 (2.1%) 26 (2.1%) 11
Placebo/Folfiri (N=614) Aflibercept/Folfiri (N=612) All (N=1226) Region Number 614 612 1226 Western Europe 217 (35.3%) 208 (34.0%) 425 (34.7%) Eastern Europe 136 (22.1%) 161 (26.3%) 297 (24.2%) North America 75(12.2%) 63 (10.3%) 138(11.3%) South America 56 (9.1%) 62 (10.1%) 118 (9.6%) Other countries 130 (21.2%) 118(19.3%) 248 (20.2%) Note: Other countries = Australia, New Zeland, South Africa and Korea 2012247530 03 Apr 2017
Disease characteristics at initial diagnosis and time from diagnosis to randomization were similar in the 2 treatment arms (Table 2).
Table 2 - Disease characteristics at initial diagnosis - ITT population
Placebo/Folfiri (N=614) Aflibercept/Folfiri (N=612) All (N=1226) Primary site [n(%)] Number 614 612 1226 Colon 302 (49.2%) 289 (47.2%) 591 (48.2%) Recto sigmoid 136 (22.1%) 123 (20.1%) 259 (21.1%) Rectum 174 (28.3%) 197 (32.2%) 371 (30.3%) Other 2 (0.3%) 3 (0.5%) 5 (0.4%) - cea &amp; ck20 postive -presumed colorectal primary 1 (0.2%) 0 1 (<0.1%) - Appendix 0 1 (0.2%) 1 (<0.1%) - Colon plus appendix 0 1 (0.2%) 1 (<0.1%) - Presumed colorectal,cea positive and history of colon cancer>20 years ago 0 1 (0.2%) 1 (<0.1%) - Synchronous primary, cecum and rectum 1 (0.2%) 0 1 (<0.1%) 2012247530 03 Apr 2017 12 Placebo/Folfiri (N=614) Aflibercept/Folfiri (N=612) All (N=1226) Histology type [n(%)] Number 614 612 1226 Adenocarcinoma 614 (100%) 612 (100%) 1226 (100%) Time from 1st diagnosis to randomization (months) [n(%)]* Number 614 611 1225 Mean (SD) 20.88 (21.10) 20.98 (24.08) 20.93 (22.62) Median 13.67 14.62 14.26 Min : Max 2.4 : 214.7 2.1 : 325.1 2.1 : 325.1 *lf the day of initial date of diagnosis is missing, it is considered as the first day of the month
Patient accountability
Overall, 30.4% of the randomized patients were allocated in the prior bevacizumab stratum (Table 3).
Table 3 - Summary of randomized patients by stratification factor (as per IVRS) 5 - ITT population
Stratification factors Placebo/Folfiri (N=614) Aflibercept/Folfiri (N=612) All (N=1226) ECOG PS [n(%)] 0 350 (57.0%) 349 (57.0%) 699 (57.0%) 1 250 (40.7%) 250 (40.8%) 500 (40.8%) 2 14 (2.3%) 13 (2.1%) 27 (2.2%) Prior Bevacizumab [n(%)] Yes 187 (30.5%) 186 (30.4%) 373 (30.4%) No 427 (69.5%) 426 (69.6%) 853 (69.6%) Note: ECOG: Eastern Cooperative Oncology Group, PS: Performance Status, IVRS: Interactive Voice response System
Dosage and duration
The median overall study treatment exposure (i.e. either both study drugs aflibercept/placebo and FOLFIRI, or one of them alone) was 8.0 and 9.0 cycles in the placebo and aflibercept treatment arms, respectively (Table 4). 2012247530 03 Apr 2017 13
Table 4 - Summary of overall study treatment exposure - Safety population
Placebo/Folfiri (N=605) Aflibercept/Folfiri (N=611) Number of cycles received by patient Sum 6127 6358 Mean (SD) 10.1 (8.1) 10.4 (7.6) Median 8.0 9.0 Min : Max 1 :67 1 :50 SD: standard deviation
The median number of aflibercept/placebo infusions was 8.0 and 7.0 in the placebo and aflibercept treatment arms, respectively (Table 5). The median relative dose intensity was 83% with aflibercept as compared to 92% with placebo. 5 Table 5 - Exposure to Aflibercept/Placebo - Safety population
Placebo/Folfiri (N=605) Aflibercept/Folfiri (N=611) Number of cycles received by patient Sum 6035 5632 Mean (SD) 10.0 (8.0) 9.2 (7.2) Median 8.0 7.0 Min : Max 1 :67 1 :35 1 24 (4.0%) 43 (7.0%) 2 32 (5.3%) 52 (8.5%) 3 85(14.0%) 70 (11.5%) 4 31 (5.1%) 45 (7.4%) 5 32 (5.3%) 43 (7.0%) 6 45 (7.4%) 29 (4.7%) 7 29 (4.8%) 28 (4.6%) 8 34 (5.6%) 29 (4.7%) 9 45 (7.4%) 29 (4.7%) 10 21 (3.5%) 28 (4.6%) 11-15 112(18.5%) 94(15.4%) 16-20 57 (9.4%) 68(11.1%) 21-25 28 (4.6%) 34 (5.6%) >25 30 (5.0%) 19 (3.1%) 2012247530 03 Apr 2017 14
Placebo/Folfiri (N=605) Aflibercept/Folfiri (N=611) Duration of exposure to aflibercept/placebo (weeks) Number 605 611 Mean (SD) 22.3(17.5) 21.7(16.7) Median 18.0 17.9 Min : Max 2 :135 2 :85 Total cumulative dose received (mg/kg) Number 605 611 Mean (SD) 39.63 (31.65) 35.69 (27.96) Median 32.00 28.00 Min : Max 0.6 : 266.4 3.8 : 140.0 Actual dose intensity (mg/kg/week) Number 605 611 Mean (SD) 1.78 (0.25) 1.55 (0.44) Median 1.84 1.66 Min : Max 0.3 :2.1 0.1 :2.1 Relative dose intensity Number 605 611 Mean (SD) 0.89 (0.12) 0.78 (0.22) Median 0.92 0.83 Min : Max 0.2 : 1.1 0.1 : 1.1 Number of cycles received: Number of cycles with at least one dose infusion of aflibercept/placebo.
The median number of irinotecan infusions was 8.0 and 9.0 in the placebo and aflibercept treatment arms, respectively (table 6). The median relative dose intensity was 84% in the aflibercept arm as compared to 91% in the placebo arm. Of note, two patients did not receive irinotecan; the dose was considered equal to 0 for the 5 calculation of the cumulative dose, actual and relative dose intensity. 2012247530 03 Apr 2017 15
Table 6 - Exposure to irinotecan- Safety population Placebo/Folfiri (N=605) Aflibercept/Folfiri (N=611) Number of cycles received by patient Sum 5992 6157 Mean (SD) 9.9 (7.8) 10.1 (7.4) Median 8.0 9.0 Min : Max 1 :67 1 :50 1 23 (3.8%) 34 (5.6%) 2 29 (4.8%) 39 (6.4%) 3 87(14.4%) 64(10.5%) 4 33 (5.5%) 36 (5.9%) 5 29 (4.8%) 37 (6.1%) 6 48 (7.9%) 31 (5.1%) 7 27 (4.5%) 27 (4.4%) 8 32 (5.3%) 29 (4.8%) 9 47 (7.8%) 29 (4.8%) 10 21 (3.5%) 38 (6.2%) 11-15 114 (18.9%) 111 (18.2%) 16-20 58 (9.6%) 78(12.8%) 21-25 31 (5.1%) 35 (5.7%) >25 25 (4.1%) 22 (3.6%) Duration of exposure to irinotecan (weeks) Number 604 610 Mean (SD) 22.2 (17.2) 23.5(16.9) Median 18.1 21.0 Min : Max 2 : 135 2 : 105 Total cumulative dose received (mg/m2) Number 605 611 Mean (SD) 1736.30 (1355.52) 1730.37 (1273.76) Median 1440.00 1472.50 Min : Max 0.0 : 11948.1 0.0 : 9046.1 2012247530 03 Apr 2017 16
Placebo/Folfiri (N=605) Aflibercept/Folfiri (N=611) Actual dose intensity (mg/m2/week) Number 605 611 Mean (SD) 78.82 (11.74) 73.59(13.68) Median 82.08 75.60 Min : Max 0.0 : 95.0 0.0 : 95.0 Relative dose intensity Number 605 611 Mean (SD) 0.88 (0.13) 0.82 (0.15) Median 0.91 0.84 Min : Max 0.0 : 1.1 0.0 : 1.1 Number of cycles received: Number of cycles with at least one dose infusion of irinotecan.
The median number of 5-FU infusions was 8.0 and 9.0 in the placebo and aflibercept treatment arms, respectively (Table 7). The median relative dose intensity was 83% in the aflibercept arm as compared to 91% in the placebo arm. Of note, two patients did not receive 5-FU; the dose was considered equal to 0 for the calculation of the 5 cumulative dose, actual and relative dose intensity.
Table 7 - Exposure to 5-FU - Safety population
Placebo/Folfiri (N=605) Aflibercept/Folfiri (N=611) Number of cycles received by patient Sum 6030 6155 Mean (SD) 10.0 (7.9) 10.1 (7.4) Median 8.0 9.0 Min : Max 1 :67 1 :50 2012247530 03 Apr 2017 17
Placebo/Folfiri (N=605) Aflibercept/Folfiri (N=611) 1 22 (3.6%) 35 (5.7%) 2 28 (4.6%) 39 (6.4%) 3 88 (14.6%) 63 (10.3%) 4 33 (5.5%) 35 (5.7%) 5 28 (4.6%) 37 (6.1%) 6 48 (8.0%) 32 (5.2%) 7 27 (4.5%) 28 (4.6%) 8 33 (5.5%) 28 (4.6%) 9 47 (7.8%) 29 (4.7%) 10 20 (3.3%) 39 (6.4%) 11-15 114 (18.9%) 113 (18.5%) 16-20 59 (9.8%) 77(12.6%) 21-25 28 (4.6%) 35 (5.7%) >25 28 (4.6%) 21 (3.4%) Duration of exposure to 5-FU (weeks) Number 603 611 Mean (SD) 22.4 (17.5) 23.5(16.9) Median 18.1 21.0 Min : Max 2 : 135 2 : 105 Total cumulative dose received (mg/m2) Number 605 611 Mean (SD) 27142.02 (21341.89) 26644.81 (19245.24) Median 22400.00 22702.44 Min : Max 0.0 : 185874.8 409.0 : 126701.4 Actual dose intensity (mg/m2/week) Number 605 611 Mean (SD) 1227.42 (190.51) 1140.36 (214.35) Median 1276.38 1165.56 Min : Max 0.0 : 1477.3 177.0 : 1491.3 2012247530 03 Apr 2017 18
Placebo/Folfiri (N=605) Aflibercept/Folfiri (N=611) Relative dose intensity Number 605 611 Mean (SD) 0.88 (0.14) 0.81 (0.15) Median 0.91 0.83 Min : Max 0.0 : 1.1 0.1 : 1.1 Number of cycles received: Number of cycles with at least one dose infusion of 5-FU. Results of EFC10262 1. Overall survival
The median follow-up time at the cutoff date (07 February 2011) for the ITT population was 22.28 months (Figure 2 and Table 8). The study met its primary endpoint 5 demonstrating a significant difference in overall survival in favor of aflibercept over placebo (stratified HR: 0.817, 95.34% Cl: 0.713 to 0.937; p = 0.0032). The hazard ratio translates into a reduction of risk of death of 18.3% (95.34 Cl: 6.3% to 28.7%) with aflibercept compared to placebo. After 12 and 18 months from randomization, the estimated probabilities of being alive were 50.3% in placebo arm and 56.1% 10 aflibercept arm, and 30.9% in placebo arm and 38.5% in aflibercept arm. Median overall survival was 13.50 months vs 12.06 months in aflibercept and placebo treatment arms, respectively. Sensitivity analyses and subgroup analyses showed a very consistent treatment effect confirming robustness of results on the primary endpoint. 15 Table 8 - Overall survival (months) - Kaplan-Meier survival estimates by treatment group- Primary analysis- Stratified according to stratification factors at randomization (IVRS) - ITT population
Time to Event or Censoring Placebo/Folfiri (N=614) Aflibercept/Folfiri (N=612) Overall Number of death events, n/N(%) 460/614 (74.9%) 403/612 (65.8%) Median overall survival (95.34% Cl) (months) 12.06 (11.072 to 13.109) 13.50 (12.517 to 14.949) 2012247530 03 Apr 2017 19
Time to Event or Censoring Placebo/Folfiri (N=614) Aflibercept/Folfiri (N=612) Number of patients at risk 3 months 573 566 6 months 485 498 9 months 401 416 12 months 286 311 18 months 131 148 24 months 51 75 Survival probability (95.34% Cl) 3 months 0.935 (0.915 to 0.955) 0.931 (0.911 to 0.951) 6 months 0.791 (0.759 to 0.824) 0.819 (0.788 to 0.850) 9 months 0.654 (0.616 to 0.692) 0.687 (0.650 to 0.725) 12 months 0.503 (0.462 to 0.543) 0.561 (0.521 to 0.602) 18 months 0.309 (0.269 to 0.348) 0.385 (0.343 to 0.427) 24 months 0.187 (0.149 to 0.225) 0.280 (0.237 to 0.324) Stratified Log-Rank test p-valuea vs Placebo/Folfiri - 0.0032 Stratified Hazard ratio (95.34% Cl)a vs Placebo/Folfiri _ 0.817 (0.713 to 0.937) Cutoff date = 7 FEBRUARY 2011 Median follow-up time = 22.28 in months a: Stratified on ECOG Performance Status (0 vs 1 vs 2) and Prior Bevacizumab (yes vs no) according to IVRS . Significance threshold is set to 0.0466 using the O'Brien-Fleming alpha spending function.
Subgroup analyses of Overall survival (OS)
Subgroup analyses did not show any significant interaction (at the 2-sided 10% level) between treatment arms and stratification factors, indicating that the treatment effect 2012247530 03 Apr 2017 20 was consistent across subgroups. This is illustrated in Table 9 and in Figures 3, 4 and 5.
Table 9 - Overall survival (months) - Summary of subgroup analyses - By stratification factors as per IVRS - ITT population
Placebo/Folfiri Median (Months) (95.34% Cl) Aflibercept/Folfiri Median (Months) (95.34% Cl) Hazard Ratio (95.34% Cl) vs Placebo/Folfiri P-value for interaction a All patients 12.1 (11.07 to 13.11) 13.5(12.52 to 14.95) 0.817 (0.713 to 0.937) Prior bevacizumab No 12.4 (11.17 to 13.54) 13.9 (12.71 to 15.64) 0.788 (0.669 to 0.927) 0.7231 Yes 11.7 (9.82 to 13.77) 12.5(10.78 to 15.51) 0.862 (0.673 to 1.104) ECOG PS 0 14.1 (12.88 to 16.62) 16.9(14.78 to 18.79) 0.768 (0.635 to 0.928) 0.5668 1 10.1 (9.20 to 11.53) 10.7 (9.36 to 12.35) 0.869 (0.71 to 1.063) 2 4.4(1.97 to 10.02) 2.8 (0.92 to 9.82) 0.978 (0.43 to 2.221) Cutoff date = 7 FEBRUARY 2011 Median follow-up time = 22.28 in months a: Interaction test from the Cox proportional hazard model including the factor, treatment effect and the treatment by factor interaction 5
Treatment effect for OS was consistent across subgroups with regards to baseline characteristics at study entry. Of note, the interaction between treatment arms and the presence of liver metastasis factor was significant at 10% level, indicating a higher treatment effect in ‘liver metastasis only’ group (HR (95.34% Cl): 0.649 (0.492 to 10 0.855)) than in ‘no liver metastasis, or other metastases’ group (HR (95.34% Cl): 0.868 (0.742 to 1.015)) (quantitative interaction, p=0.0899) This is illustrated in Table 10. 2012247530 03 Apr 2017 21
Table 10 - Overall survival (months) - Summary of subgroup analyses - By baseline characteristics - ITT population Placebo/Folfiri Median (Months) (95.34% Cl) Aflibercept/Folfiri Median (Months) (95.34% Cl) Hazard Ratio (95.34% Cl) vs Placebo/Folfiri P-value for interaction3 All patients 12.1 (11.07 to 13.11) 13.5 (12.52 to 14.95) 0.817 (0.713 to 0.937) Prior hypertension No 11.7(10.41 to 13.11) 12.7 (11.17 to 14.39) 0.883 (0.74 to 1.054) 0.1309 Yes 12.7 (10.78 to 14.00) 15.5 (12.91 to 18.56) 0.714 (0.577 to 0.884) Number of metastatic organs involved > 1 10.5 (9.72 to 12.06) 12.1 (10.71 to 13.11) 0.825 (0.692 to 0.982) 0.6992 <= 1 13.7 (12.29 to 16.30) 16.0 (14.42 to 20.86) 0.767 (0.618 to 0.953) Liver Metastasis only No 12.3 (11.07 to 13.73) 13.2 (12.06 to 15.28) 0.868 (0.742 to 1.015) 0.0899 Yes 11.4 (9.86 to 12.88) 14.4 (12.68 to 18.04) 0.649 (0.492 to 0.855) Location of primary tumor Colon 10.6(9.66 to 12.06) 12.9 (11.50 to 16.16) 0.739 (0.607 to 0.899) 0.1421 Recto sigmoid/Other 14.1 (12.71 to 17.08) 14.3 (12.35 to 16.39) 1.039 (0.772 to 1.4) Rectum 12.6 (10.35 to 14.55) 13.5 (11.93 to 15.87) 0.806 (0.629 to 1.031) Median follow-up time = 22.28 in months a: Interaction test from the Cox proportional hazard model including the factor, treatment effect and the treatment by factor interaction 5 2012247530 03 Apr 2017 22
2. Progression free survival based on tumor assessment by the IRC
The final analysis for PFS was performed at the time of the second interim analysis of OS (i.e. cut off date = 06 MAY 2010). Improvement in progression free survival (PFS) was demonstrated in patients of the aflibercept treatment arm compared to patients in 5 the placebo treatment arm (stratified HR: 0.758, 99.99%CI: 0.578 to 0.995; p = 0.00007). Median PFS was 6.90 months in the aflibercept arm and 4.67 months in the placebo arm (Table 11).
Table 11 - PFS based on tumor assessment by the IRC (months) - Kaplan-Meier survival estimates by treatment group - Stratified according to stratification 10 factors at randomization (IVRS) - ITT population
Time to Event or Censoring Placebo/Folfiri (N=614) Aflibercept/Folfiri (N=612) Overall Number of events, n/N(%) 454/614 (73.9%) 393/612 (64.2%) Median PFS (99.99% Cl) (months) 4.67 (4.074 to 5.552) 6.90 (5.881 to 7.852) Number at risk 3 months 355 420 6 months 171 247 9 months 94 99 12 months 46 43 18 months 9 7 Probability of surviving (99.99% Cl) 3 months 0.664(0.587 to 0.741) 0.793 (0.727 to 0.859) 6 months 0.390 (0.306 to 0.475) 0.573 (0.488 to 0.659) 9 months 0.254 (0.174 to 0.334) 0.313 (0.222 to 0.404) 12 months 0.146 (0.076 to 0.216) 0.166 (0.085 to 0.246) 18 months 0.043 (0.000 to 0.091) 0.051 (0.000 to 0.108) Stratified Log-Rank test p-valuea vs Placebo/Folfiri - 0.00007 2012247530 03 Apr 2017 23
Time to Event or Censoring Placebo/Folfiri (N=614) Aflibercept/Folfiri (N=612) Stratified Hazard ratio (99.99% Cl)a vs Placebo/Folfiri - 0.758 (0.578 to 0.995) Cutoff date = 06 MAY 2010 a: Stratified on ECOG Performance Status (0 vs 1 vs 2) and Prior Bevacizumab (yes vs no) according to IVRS Significance threshold is set to 0.0001. Subgroup analyses of Progression free survival
Progression free survival (PFS) was analyzed in subgroups as illustrated in Table 12 and in Figure 6. No interaction between treatment arms and stratification factors was observed (Table 12). 5 Table 12 - PFS based on tumor assessment by the IRC (months) - Summary of subgroup analyses - By stratification factors as per IVRS - ITT population
Placebo/Folfiri Median (Months) (99.99% Cl) Aflibercept/ Folfiri Median (Months) (99.99% Cl) Hazard Ratio (99.99% Cl) vs Placebo/Folfiri P-value for interaction3 All patients 4.7 (4.07 to 5.55) 6.9 (5.88 to 7.85) 0.758 (0.578 to 0.995) Prior bevacizumab No 5.4 (4.17 to 6.70) 6.9 (5.82 to 8.15) 0.797 (0.58 to 1.096) 0.6954 Yes 3.9 (2.86 to 5.42) 6.7 (4.76 to 8.74) 0.661 (0.399 to 1.095) ECOG PS 0 5.4 (4.24 to 6.77) 7.2 (6.37 to 8.87) 0.761 (0.529 to 1.094) 0.1958 1 4.1 (2.83 to 5.55) 5.6 (4.60 to 7.46) 0.749 (0.494 to 1.135) 2012247530 03 Apr 2017 24
Placebo/Folfiri Median (Months) (99.99% Cl) Aflibercept/ Folfiri Median (Months) (99.99% Cl) Hazard Ratio (99.99% Cl) vs Placebo/Folfiri P-value for interaction3 2 2.0 (1.18 to 5.75) 2.7 (0.53 to 12.88) 0.618(0.11 to 3.476) Cutoff date = 06 MAY 2010 a: Interaction test from the Cox proportional hazard model including the factor, treatment effect and the treatment by factor interaction
For PFS, no significant interaction was shown between treatment arms and demographic variables or regions.
Treatment effect for PFS was consistent across subgroups with regards to baseline characteristics at study entry. Of note, the interaction between treatment arms and the 5 presence of liver metastasis factor, that was noted on OS, was also significant at 10% level, indicating a higher treatment effect ‘in liver metastasis only’ group (HR (99.99%CI): 0.547 (0.313 to 0.956)) than in ‘no liver metastasis, or other metastases’ group (HR (99.99%CI): 0.839 (0.617 to 1.143)) (quantitative interaction, p=0.0076).
Results of the two sensitivity analyses for PFS were consistent with those of the 10 primary PFS analysis. Moreover, adherence to the protocol-defined schedule for tumor assessment was assessed and showed no imbalance between treatment arms. 3. Overall Response rate
Overall response rate -IRC reviewed- was significantly higher in the aflibercept treatment arm when compared to the placebo treatment arm: 19.8% (95%CI: 16.4% 15 to 23.2%) vs 11.1 % (95%CI: 8.5% to 13.8%) respectively (p=0.0001) (Table 13).
Table 13 - Summary of overall objective response rate by IRC - Evaluable patient population for response rate 2012247530 03 Apr 2017 25
Placebo/Folfiri (N=530) Aflibercept/Folfiri (N=531) Best Overall Response [n(%)] Complete response 2 (0.4%) 0 Partial response 57(10.8%) 105(19.8%) Stable disease 344 (64.9%) 350 (65.9%) Progressive disease 114(21.5%) 55(10.4%) Not evaluable 13 (2.5%) 21 (4.0%) Overall Response Responders (Complete response or Partial response) 59(11.1%) 105(19.8%) 95% Cla 8.5% to 13.8% 16.4% to 23.2% Stratified Cochran-Mantel-Haenszel test p-valueb Vs Placebo/Folfiri - 0.0001 Estimated by Normal approximation bStratified on ECOG Performance Status (0 vs 1 vs 2) and Prior Bevacizumab (yes vs no) according to IVRS. 4. Further anti-cancer therapy
Overall 60% of patients in both treatment groups received further antitumor therapies (Table 14). 5 Table 14 - Summary of first further anti-cancer therapies - ITT population
Placebo/Folfiri (N=614) Aflibercept/Folfiri (N=612) At least one further therapy [n(%)] Yes 366 (59.6%) 364 (59.5%) No 248 (40.4%) 248 (40.5%) Type of first further therapy [n(%)] Systemic anti-cancer treatment 303/366 (82.8%) 296/364 (81.3%) Radiotherapy 43/366 (11.7%) 34/364 (9.3%) Surgery 20/366 (5.5%) 34/364 (9.3%) 2012247530 03 Apr 2017 26
Placebo/Folfiri (N=614) Aflibercept/Folfiri (N=612) Time from last IV to first further systemic anti-cancer therapy (months)3 Number 297 293 Mean (SD) 1.87(1.71) 2.37 (2.45) Median 1.35 1.58 Min : Max 0.3 : 14.0 0.2 : 20.5 Time from last IV to first further radiotherapy (months)3 Number 43 33 Mean (SD) 3.02 (3.86) 3.25 (3.38) Median 1.31 2.07 Min : Max 0.4 : 16.5 0.6 : 14.6 Time from last IV to first further surgery (months)3 Number 20 34 Mean (SD) 1.62(1.41) 2.42 (2.08) Median 1.15 1.48 Min : Max 0.4 : 7.2 0.2 : 8.5 Systemic anti-cancer therapies include chemotherapy and biologies. Only the earliest date of further therapy in each category (systemic anti-cancer treatment, radiotherapy or surgery) is kept aTime from last IV to first futher therapy is not calculated for patients randomized but not treated.
About 32% of patients in each group receive further anticancer treatment that includes a “biologic (Table 15).
Table 15 - Summary of all further anti-cancer therapies - ITT population
Placebo/Folfiri (N=614) Aflibercept/Folfiri (N=612) Any further therapy 366 (59.6%) 364 (59.5%) Surgery 31 (5.0%) 47 (7.7%) Radiotherapy 81 (13.2%) 79 (12.9%) 2012247530 03 Apr 2017 27
Placebo/Folfiri (N=614) Aflibercept/Folfiri (N=612) Systemic anti-cancer treatment 329 (53.6%) 329 (53.8%) Biologies / Small molecules 197 (32.1%) 195 (31.9%) Cetuximab 91 (14.8%) 108 (17.6%) Bevacizumab 75(12.2%) 55 (9.0%) Panitumumab 52 (8.5%) 52 (8.5%) Other 14 (2.3%) 21 (3.4%) Chemotherapy 297 (48.4%) 287 (46.9%) Fluoropyrimidine 233 (37.9%) 223 (36.4%) Irinotecan 160 (26.1%) 174 (28.4%) Other 79 (12.9%) 71 (11.6%) Oxaliplatin 66(10.7%) 53 (8.7%) Other3 6 (1.0%) 5 (0.8%) 3: include patients randomized in placebo control trials for whom exact nature of the treatment is unknown A patient can be counted both in chemotherapy and biologies (categories can not be added). 5. Safety Adverse events
Treatment emergent adverse events, all grades, were reported in nearly 100% of the patients in both treatment arms, whereas occurence of grade 3-4 events was greater 5 in the aflibercept treatment arm (83.5% vs 62.5%).
The rate of permanent discontinuation of study treatment due to adverse events was higher in the aflibercept treatment arm (26.8% vs 12.1%). A similar pattern was observed for premature treatment discontinuation due to adverse events (19.5% vs 2.8%). Premature treatment discontinuation corresponds to an earlier discontinuation 10 of either FOLFIRI, aflibercept/placebo being continued, or aflibercept/placebo, FOLFIRI being continued.
Within 30 days of last dosing, respectively 37 (6.1%) and 29 (4.8%) patients in the aflibercept and placebo arm, respectively, experienced, adverse events that eventually led to death within 30 days (28 vs 17 in the aflibercept and placebo arm, 15 respectively) or after 30 days (9 vs 12 in the placebo and aflibercept arm, respectively) of last dosing. These included death due to disease progression. 28 2012247530 03 Apr 2017 A summary of safety data is illustrated in Table 16 and Table 17.
Table 16 - Summary of the most frequent TEAEs: incidence > 20% in aflibercept arm or (incidence < 20% in aflibercept arm and Δ all grades >5 %) - Safety population
% of patients (in the safety population) Placebo/Folfiri N = 605 Aflibercept/Fol firi N = 611 Δ>10% all Gr 5<Δ<10 % all Gr Δ>2% Gr 3/4 All Gr Gr 3/4 All Gr Gr 3/4 Incidence >20% (aflibercept arm) Diarrhea (PT) 56.5 7.8 69.2 19.3 X X Asthenic condition (HLT) 50.2 10.6 60.4 16.9 X X Stomatitis &amp; ulceration (HLT) 34.9 5.0 54.8 13.7 X X Nausea(PT) 54.0 3.0 53.4 1.8 Infections (SOC) 32.7 6.9 46.2 12.3 X X Hypertensio n (grouping) 10.7 1.5 41.4 19.3 X X Gl and abdominal pains (HLT) 29.1 3.3 34.0 5.4 Vomiting (PT) 33.4 3.5 32.9 2.8 Decrease appetite (PT) 23.8 1.8 31.9 3.4 X Weight decrease (PT) 14.4 0.8 31.9 2.6 X Epistaxis (PT) 7.4 0 27.7 0.2 X Alopecia (PT) 30.1 NA 26.8 NA Dysphonia (PT) 3.3 0 25.4 0.5 X 2012247530 03 Apr 2017 29 % of patients (in the safety population) Placebo/Folfiri N = 605 Aflibercept/Fol firi N = 611 Δ>10% all Gr 5<Δ<10 % all Gr Δ>2% Gr 3/4 All Gr Gr 3/4 All Gr Gr 3/4 Incidence >20% (aflibercept arm) Musculoskel etal &amp; connective pain &amp; discomfort (HLT) 21.2 2.3 23.1 1.3 Constipation (PT) 24.6 1.0 22.4 0.8 Headache (PT) 8.8 0.3 22.3 1.6 X Incidence < 20 % (aflibercept arm) and Δ all grades > 5 % Palmar plantar erythrodysa esthesia (PT) 4.3 0.5 11.0 2.8 X Dehydration (PT) 3.0 1.3 9.0 4.3 X Skin hyperpigme ntation (PT) 2.8 0 8.2 0 X Medra classification: SOC (system organ class), HLT (high level term), ΡΊ (Preferred term). Grouping: grouping of selected PTs Δ: difference in incidence in aflibercept arm compared to placebo Table 17 - Overview of safety, number (%) of patients - Safety population
Placebo/Folfiri (N=605) Aflibercept/Folfiri (N=611) Patients with any TEAE 592 (97.9%) 606 (99.2%) Patients with any grade 3-4 TEAE 378 (62.5%) 510 (83.5%) Patients with any serious TEAE 198 (32.7%) 294 (48.1%) Patients with any TEAE leading to death 29 (4.8%) 37 (6.1%) Patients with any related TEAE leading to death 3 (0.5%) 6 (1.0%) Patients with any TEAE leading to permanent treatment discontinuation 73 (12.1%) 164 (26.8%) 2012247530 03 Apr 2017 30
Placebo/Folfiri (N=605) Aflibercept/Folfiri (N=611) Patients with any TEAE leading to premature treatment discontinuation 17 (2.8%) 119(19.5%) Note : Adverse Events are reported using graded using NCI CTC Version 3.0. VledDRA version IV EDDRA13.1 and 5. Conclusions
The study met its primary endpoint, with a significant improvement in overall survival in the aflibercept arm when compared to placebo.
In addition, a significant improvement was demonstrated on secondary efficacy 5 endpoints (PFS and RR).
The safety profile was qualitatively consistent with that of anti VEGF treatment with enhancement of known toxicities of the background chemotherapy (such as diarrhea, stomatitis, infections, neutropenia/neutropenic complications).

Claims (24)

1. A method of treating Colorectal Cancer (CRC) or Colorectal Cancer (CRC) symptom in a patient in need thereof, said method comprising administering to said patient therapeutically effective amounts of aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinotecan.
2. A method of increasing Overall Survival (OS) in a patient afflicted with CRC, said method comprising administering to said patient therapeutically effective amounts of aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinotecan.
3. A method of increasing Progression Free Survival (PFS) in a patient afflicted with CRC, said method comprising administering to said patient therapeutically effective amounts of aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinotecan.
4. A method of increasing Overall Response Rate (ORR) in a patient afflicted with CRC, said method comprising administering to said patient therapeutically effective amounts of aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinotecan.
5. A method according to any one of claims 1 to 4 which is safe and effective.
6. A method according to any one of claims 1 to 5 wherein said patient has already been treated for the CRC or CRC symptom.
7. A method according to any one of claims 1 to 6 wherein said patient has previously been treated with chemotherapy, radiotherapy or surgery.
8. A method according to any one of claims 1 to 7 wherein said patient has previously been treated with therapy based on oxaliplatin or on bevacizumab.
9. A method according to any one of claims 7 and 8 wherein said patient has failed with chemotherapy, radiotherapy or surgery.
10. A method according to any one of claims 1 to 9 wherein CRC is a Metastatic CRC.
11. A method according to any one of claims 1 to 10 wherein folinic acid at a dosage comprised between about 200 mg/m2 and about 600 mg/m2, 5-fluorouracil (5-FU) at a dosage comprised between about 2000 mg/m2 and about 4000 mg/m2 , irinotecan at a dosage comprised between about 100 mg/m2 and about 300 mg/m2 and aflibercept at a dosage comprised between about 1 mg/kg and about 10 mg/kg are administered to patient.
12. A method according to any one of claims 1 to 1 1 wherein folinic acid at a dosage of about 400 mg/m2, 5-fluorouracil (5-FU) at a dosage of about 2800 mg/m2, irinotecan at a dosage of about 180 mg/m2 and aflibercept at a dosage of about 4 mg/kg are administered to patient.
13. A method according to any one of claims 1 to 12 wherein folinic acid is administered intravenously at a dosage of about 400 mg/m2, 5-fluorouracil (5-FU) is administered intravenously at a dosage of about 2800 mg/m2, irinotecan is administered intravenously at a dosage of about 180 mg/m2 and aflibercept is administered intravenously at a dosage of about 4 mg/kg and wherein the combination is administered every two weeks.
14. A method according to any one of claims 1 to 13 wherein the folinic acid, 5- fluorouracil (5-FU), irinotecan and aflibercept are administered intravenously every two weeks for a period comprised between 9 and 18 weeks.
15. A method according to any one of claims 1 to14 wherein the folinic acid is administered intravenously immediately after aflibercept administration.
16. A method according to any one of claims 1 to 15 wherein the folinic acid is administered intravenously immediately after aflibercept administration over a period of about 2 hours.
17. A method according to any one of claims 1 to 16 wherein the irinotecan is administered intravenously immediately after aflibercept administration.
18. A method according to any one of claims 1 to 17 wherein the irinotecan is administered intravenously immediately after aflibercept administration over a period of about 90 minutes
19. A method according to any one of claims 1 to 18 wherein the 5-fluorouracil (5- FU) is administered immediately after aflibercept administration.
20. A method according to any one of claims 1 to 19 wherein a first quantity of 5- fluorouracil (5-FU) is administered intravenously immediately after aflibercept administration and a second quantity of 5-FU is administered intravenously after the first quantity in continuous infusion.
21. A method according to any one of claims 1 to 20 wherein about 400 mg/m2 of 5- fluorouracil (5-FU) is administered intravenously over a period of 2 to 4 minutes after aflibercept administration and wherein 2400 mg/m2 of 5-FU is administered intravenously over almost 46 hours after the administration of the 400 mg/m2 in continuous infusion.
22. A method according to any one of claims 1 to 21 wherein the patient has liver metastases.
23. Composition when used in the treatment of patients with CRC comprising therapeutically effective amounts of aflibercept in combination with folinic acid, 5-flurouracil and irinotecan and comprising a pharmaceutically acceptable carrier wherein the composition is formulated so as to deliver folinic acid at a dosage between 200 mg/m2 and 600 mg/m2, 5-fluorouracil (5-FU) at a dosage between 2000 mg/m2 and 4000 mg/m2, irinotecan at a dosage between 100 mg/m2 and 300 mg/m2 and aflibercept at a dosage between 1 mg/kg and 10 mg/kg such that efficacy of medical outcomes is significantly improved.
24. A kit of pharmaceutical compositions when used to achieve significantly improved efficacy in treating CRC in a patient comprising (1) a pharmaceutical composition comprising aflibercept such that aflibercept at a dosage between 1 mg/kg and 10 mg/kg is administered (2) a pharmaceutical composition comprising folinic acid such that folinic acid at a dosage between 200 mg/m2 and 600 mg/m2 is used, (3) a pharmaceutical composition comprising 5-fluorouracil (5-FU) such that 5-fluorouracil (5-FU) at a dosage between 2000 mg/m2 and 4000 mg/m2 is used and (4) a pharmaceutical composition comprising irinotecan such that irinotecan at a dosage between 100 mg/m2 and 300 mg/m2. SANOFI WATERMARK PATENT AND TRADE MARKS ATTORNEYS P37407AU00
AU2012247530A 2011-04-26 2012-04-25 Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinocetan (FOLFIRI) Active AU2012247530B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11305490.2 2011-04-26
EP11305490 2011-04-26
EP11306154.3 2011-09-15
EP11306154 2011-09-15
PCT/EP2012/057542 WO2012146610A1 (en) 2011-04-26 2012-04-25 Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri)

Publications (2)

Publication Number Publication Date
AU2012247530A1 AU2012247530A1 (en) 2013-05-02
AU2012247530B2 true AU2012247530B2 (en) 2017-05-11

Family

ID=46001286

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012247530A Active AU2012247530B2 (en) 2011-04-26 2012-04-25 Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinocetan (FOLFIRI)

Country Status (39)

Country Link
US (1) US11033606B2 (en)
EP (2) EP3210617A1 (en)
JP (1) JP6114257B2 (en)
KR (2) KR102002653B1 (en)
CN (1) CN103608029A (en)
AR (1) AR086051A1 (en)
AU (1) AU2012247530B2 (en)
BR (1) BR112013027356A2 (en)
CA (1) CA2833592A1 (en)
CL (1) CL2013003082A1 (en)
CO (1) CO6811861A2 (en)
CR (1) CR20130547A (en)
CY (1) CY1120382T1 (en)
DK (1) DK2701724T3 (en)
DO (1) DOP2013000248A (en)
EA (1) EA025182B1 (en)
EC (1) ECSP13013044A (en)
ES (1) ES2637074T3 (en)
GT (1) GT201300260A (en)
HR (1) HRP20171216T1 (en)
HU (1) HUE034288T2 (en)
IL (2) IL228947B (en)
JO (1) JO3283B1 (en)
LT (1) LT2701724T (en)
MA (1) MA35130B1 (en)
MX (1) MX341348B (en)
NI (1) NI201300112A (en)
PE (2) PE20140616A1 (en)
PH (1) PH12013502195A1 (en)
PL (1) PL2701724T3 (en)
PT (1) PT2701724T (en)
RS (1) RS56177B1 (en)
SG (2) SG194613A1 (en)
SI (1) SI2701724T1 (en)
TW (1) TWI599369B (en)
UA (1) UA114708C2 (en)
UY (1) UY34036A (en)
WO (1) WO2012146610A1 (en)
ZA (1) ZA201308821B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3283B1 (en) 2011-04-26 2018-09-16 Sanofi Sa Composition including Afflipersept, Folinic Acid, 5- Fluorouracil (5- Fu) and Irenosetan (FOLFIRI)
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) * 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
HK1206628A1 (en) * 2012-08-02 2016-01-15 Sanofi Article of manufacture comprising aflibercept or ziv-aflibercept
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
ES2732925T3 (en) * 2014-07-18 2019-11-26 Sanofi Sa Method to predict the result of aflibercept treatment of a patient suspected of suffering from cancer
WO2016044041A1 (en) 2014-09-16 2016-03-24 Regeneron Pharmaceuticals, Inc. Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
WO2017031442A1 (en) 2015-08-20 2017-02-23 Merrimack Pharmaceuticals, Inc. Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
JP2018528185A (en) 2015-08-21 2018-09-27 イプセン バイオファーム リミティド Method for treating metastatic pancreatic cancer using combination therapy comprising liposomal irinotecan and oxaliplatin
KR101936049B1 (en) * 2015-10-15 2019-01-08 (주)알테오젠 Method for manufacturing fusion proteins with IgG Fc domain
KR20250057128A (en) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 Antibodies and conjugates thereof
EA037406B1 (en) * 2016-01-25 2021-03-25 Санофи Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer by measuring the level of a plasma biomarker
KR20190077441A (en) 2016-11-02 2019-07-03 입센 바이오팜 리미티드 Gastric cancer treatment using combination therapy including liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin)
MX2020009152A (en) 2018-03-02 2020-11-09 Kodiak Sciences Inc IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF.
KR20210021299A (en) 2018-05-10 2021-02-25 리제너론 파아마슈티컬스, 인크. Formulation containing high concentration VEGF receptor fusion protein
EP3801513A1 (en) * 2018-05-30 2021-04-14 Machover, David Methods and pharmaceutical compositions for treating cancer
WO2021050094A1 (en) * 2019-09-11 2021-03-18 Adverum Biotechnologies, Inc. Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept
CN114786731A (en) 2019-10-10 2022-07-22 科达制药股份有限公司 Methods of treating ocular disorders

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790B2 (en) 1977-11-18 1985-05-17 株式会社日立製作所 Photocurable adhesive composition and method for bonding adherends using it
US4353887A (en) 1979-08-16 1982-10-12 Ciba-Geigy Corporation Divisible tablet having controlled and delayed release of the active substance
JPS6019790A (en) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd Novel camptothecin derivative
AU2309692A (en) 1991-07-03 1993-02-11 Cryolife, Inc. Method for stabilization of biomaterials
US5474796A (en) 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
WO1993022336A1 (en) 1992-04-30 1993-11-11 Alpha Therapeutic Corporation Improved solubilization and stabilization of factor viii complex
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
ATE281469T1 (en) 1993-03-25 2004-11-15 Merck & Co Inc INHIBITOR OF THE GROWTH FACTOR FOR VASCULAR ENDOTHELIAL CELLS
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US6040157A (en) 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
GB9410534D0 (en) 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
GB9410533D0 (en) 1994-05-26 1994-07-13 Lynxvale Ltd In situ hybridisation and immuno-Chemical localisation of a growth factor
TW438775B (en) 1995-04-07 2001-06-07 Pharmacia & Upjohn Co Llc Novel intermediates and process for the manufacture of camptothecin derivatives (CPT-11) and related compounds
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JPH09154588A (en) 1995-10-07 1997-06-17 Toagosei Co Ltd Vegf-binding polypeptide
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
CA2266419A1 (en) 1996-09-24 1998-04-02 Merck & Co., Inc. Gene therapy for inhibition of angiogenesis
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
DE19724793A1 (en) 1997-06-06 1998-12-10 Schering Ag New peptides inhibit vascular endothelial cell growth factor
US6075007A (en) 1997-07-17 2000-06-13 Regeneron Pharmaceuticals, Inc. Modified noggin polypeptide and compositions
JPH1180024A (en) 1997-09-12 1999-03-23 Toagosei Co Ltd Corneal vascular rebirth inhibitor
US6436897B2 (en) 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
DE19841985A1 (en) 1998-09-03 2000-03-09 Schering Ag New heterocyclic alkanesulfonic and alkane carboxylic acid derivatives are VEGF receptor blockers useful in treatment of e.g. psoriasis, rheumatoid arthritis, stroke, tumors and endometriosis
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
WO2000034337A1 (en) 1998-12-10 2000-06-15 Tsukuba Research Laboratory, Toagosei Co., Ltd. Humanized monoclonal antibodies against vascular endothelial cell growth factor
AP1243A (en) 1999-02-01 2004-02-02 Servier Lab Core tablet for controlled release of gliclazide after oral administration.
WO2000064946A2 (en) 1999-04-28 2000-11-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
WO2000066125A1 (en) 1999-04-29 2000-11-09 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
CA2376379C (en) 1999-06-08 2007-08-07 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6833349B2 (en) 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7001892B1 (en) 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
DE19938724A1 (en) 1999-08-16 2001-02-22 Tetra Laval Holdings & Finance Device for the production of plastic containers by means of stretch blow molding
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
US6500633B1 (en) 2000-04-26 2002-12-31 Atairgin Technologies, Inc. Method of detecting carcinomas
GT200100079A (en) 2000-05-10 2001-12-31 METHOD FOR REGULATING ANGIOGENESIS USING RYK PROTEIN
IL155002A0 (en) 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
US20030092019A1 (en) 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
US20040023864A1 (en) 2001-05-09 2004-02-05 Steve Roczniak Method of regulating angiogenesis using ryk protein
CA2454587C (en) 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
DE60314378T2 (en) 2002-03-01 2008-02-28 Pfizer Italia S.R.L. CRYSTALLINE POLYMORPHIC FORM OF IRINOTECANHYDROCHLORIDE
JP2004006671A (en) 2002-03-22 2004-01-08 Sanyo Electric Co Ltd Charge coupled device and method of manufacturing the same
AU2004226417B2 (en) 2003-03-28 2009-01-22 Regeneron Pharmaceuticals, Inc. Methods of treating diabetes by blocking VEGF-mediated activity
DK2335725T3 (en) 2003-04-04 2017-01-23 Genentech Inc Highly concentrated antibody and protein formulations
US7300654B2 (en) 2003-05-28 2007-11-27 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection in high risk keratoplasty patients
AU2004242586C1 (en) 2003-05-28 2011-02-24 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection by using VEGF antagonists
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
US7354578B2 (en) 2003-06-06 2008-04-08 Regeneron Pharmaceuticals, Inc. Method of tumor regression with VEGF inhibitors
US7399612B2 (en) 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
AR046510A1 (en) * 2003-07-25 2005-12-14 Regeneron Pharma COMPOSITION OF A VEGF ANTAGONIST AND AN ANTI-PROLIFERATIVE AGENT
US20050196340A1 (en) 2003-08-06 2005-09-08 Jocelyn Holash Use of a VEGF antagonist in combination with radiation therapy
US20050112061A1 (en) 2003-08-06 2005-05-26 Jocelyn Holash Use of a VEGF antagonist in combination with radiation therapy
DE60336765D1 (en) 2003-08-14 2011-05-26 Fujitsu Ltd COMPUTER DEVICE AND CLUSTER SERVER DEVICE
SI1660057T1 (en) 2003-08-27 2012-10-30 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
DE60326353D1 (en) 2003-11-06 2009-04-09 Nestle Waters Man & Technology Production process of polyester resin containers
US7582726B2 (en) 2003-11-10 2009-09-01 Ghc Research Development Corporation VEGF receptor antagonists
WO2005072772A1 (en) 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Pharmaceutical compositions
US7354580B2 (en) 2004-06-10 2008-04-08 Regeneron Pharmaceuticals, Inc. Method of administering and using VEGF inhibitors for the treatment of human cancer
AU2005265071A1 (en) 2004-06-18 2006-01-26 Memorial Sloan-Kettering Cancer Center VEGF inhibitors for the treatment of malignant pleural effusion
US7378095B2 (en) 2004-07-30 2008-05-27 Regeneron Pharmaceuticals, Inc. Methods of treating type I diabetes by blocking VEGF-mediated activity
EP2324848A3 (en) 2004-10-21 2011-09-14 Genentech, Inc. Method for treating intraocular neovascular diseases
FR2878749B1 (en) * 2004-12-03 2007-12-21 Aventis Pharma Sa ANTITUMOR COMBINATIONS CONTAINING IN VEGT INHIBITOR AGENT AND 5FU OR ONE OF ITS DERIVATIVES
AU2006214658A1 (en) 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a VEGF inhibitor
AU2006213856B2 (en) 2005-02-11 2011-03-17 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a VEGF antagonist (VEGF trap) and an anti-hypertensive agent
EP1855708A1 (en) 2005-03-11 2007-11-21 Regeneron Pharmaceuticals, Inc. Treating anemia by inhibition of vegf
CN102614134B (en) 2005-03-25 2016-09-07 瑞泽恩制药公司 VEGF antagonist preparation
RU2414924C2 (en) 2005-08-12 2011-03-27 Ридженерон Фармасьютикалз, Инк. Method of treating diseases by vegf antagonists
US7354582B2 (en) 2006-03-10 2008-04-08 Regeneron Pharmaceuticals, Inc. Use of VEGF antagonists for the treatment of malignant gliomas
RU2432155C3 (en) 2006-06-16 2017-11-17 Ридженерон Фармасьютикалз, Инк. VEGF ANTAGONIST COMPOSITIONS SUITABLE FOR INTRAVITREAL INTRODUCTION
NO347649B1 (en) 2006-12-14 2024-02-12 Regeneron Pharma Human antibody or antibody fragment that specifically binds human delta-like ligand 4 (hDII4), nucleic acid molecule that codes for such and vector and host-vector systems, as well as method for production, composition and use.
EP2136630A4 (en) 2007-03-23 2010-06-02 Precision Therapeutics Inc Methods for evaluating angiogenic potential in culture
FR2918279B1 (en) 2007-07-05 2010-10-22 Aventis Pharma Sa ANTITUMOR COMBINATIONS CONTAINING A VEGF INHIBITOR AGENT AND IRINOTECAN
CN100546578C (en) * 2007-08-10 2009-10-07 河北医科大学 A kind of anticancer drug composition and its application in the preparation of anticancer drug
RS54847B2 (en) 2007-10-04 2019-09-30 Onyx Therapeutics Inc Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
ES2372236T3 (en) 2007-11-30 2012-01-17 Genentech, Inc. VEGF POLYMORPHISMS AND ANTI-ANGIOGENESIS THERAPY.
EP2143542A1 (en) 2008-07-07 2010-01-13 Nestec S.A. Method and apparatus for packaging a liquid food product
FR2933702A1 (en) 2008-07-08 2010-01-15 Sanofi Aventis SPECIFIC ANTAGONISTS OF FGF-R4 RECEPTOR
WO2010022201A2 (en) 2008-08-22 2010-02-25 Osteogenex Inc. Folinic acid derivatives for promoting bone growth
WO2010042903A1 (en) 2008-10-09 2010-04-15 Alfagene Bioscience, Inc Use and identification of biomarkers for gastrointestinal diseases
EP2540843B1 (en) 2008-11-05 2014-07-02 Genentech, Inc. Genetic polymorphisms in age-related macular degeneration
CN102325549A (en) 2009-03-31 2012-01-18 罗氏格黎卡特股份公司 Treatment of cancer with umanized anti-egfr igg1 antibody and irinotecan
WO2010124264A2 (en) 2009-04-24 2010-10-28 University Of Southern California Genetic variants in angiogenesis pathway associated with clinical outcome
AU2010278853B2 (en) 2009-07-31 2014-05-15 Amcor Rigid Plastics Usa, Llc Hot-fill container
US8221753B2 (en) * 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
AR085301A1 (en) 2011-02-23 2013-09-18 Sanofi Sa POLYMORPHISMS OF A SINGLE NUCLEOTIDE IN THE PROMOTER OF GEN VEGFA AND ITS USE AS PREDICTIVE MARKERS FOR ANTI-VEGF TREATMENTS
JO3283B1 (en) 2011-04-26 2018-09-16 Sanofi Sa Composition including Afflipersept, Folinic Acid, 5- Fluorouracil (5- Fu) and Irenosetan (FOLFIRI)
JP6019790B2 (en) 2012-06-19 2016-11-02 富士電機株式会社 Joining method and joining member
HK1206628A1 (en) 2012-08-02 2016-01-15 Sanofi Article of manufacture comprising aflibercept or ziv-aflibercept
ES2732925T3 (en) * 2014-07-18 2019-11-26 Sanofi Sa Method to predict the result of aflibercept treatment of a patient suspected of suffering from cancer
EA037406B1 (en) 2016-01-25 2021-03-25 Санофи Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer by measuring the level of a plasma biomarker

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Sanofi-Aventis and Regeneron Pharmaceuticals, ClinicalTrials.gov, 17/2/2011Retrieved from the Internet: URL: https://clinicaltrials.gov/archive/NCT00561470/2011_02_17 [retrieved on 18/11/2014] *

Also Published As

Publication number Publication date
CL2013003082A1 (en) 2014-05-16
SG10201610829UA (en) 2017-02-27
KR102002653B1 (en) 2019-07-24
NI201300112A (en) 2014-02-28
EA201391577A1 (en) 2014-03-31
WO2012146610A1 (en) 2012-11-01
ECSP13013044A (en) 2014-01-31
HUE034288T2 (en) 2018-02-28
PL2701724T3 (en) 2017-11-30
KR20140036193A (en) 2014-03-25
SI2701724T1 (en) 2017-10-30
MA35130B1 (en) 2014-05-02
GT201300260A (en) 2015-02-09
EP3210617A1 (en) 2017-08-30
LT2701724T (en) 2017-09-11
CR20130547A (en) 2014-02-18
PE20140616A1 (en) 2014-05-24
PH12013502195A1 (en) 2022-04-08
ES2637074T3 (en) 2017-10-10
RS56177B1 (en) 2017-11-30
SG194613A1 (en) 2013-12-30
TWI599369B (en) 2017-09-21
MX2013012387A (en) 2014-12-05
NZ617573A (en) 2015-11-27
UY34036A (en) 2012-11-30
DK2701724T3 (en) 2017-09-11
DOP2013000248A (en) 2014-02-28
UA114708C2 (en) 2017-07-25
PT2701724T (en) 2017-08-18
EA025182B1 (en) 2016-11-30
TW201247220A (en) 2012-12-01
JP6114257B2 (en) 2017-04-12
IL228947B (en) 2018-01-31
HRP20171216T1 (en) 2017-10-20
BR112013027356A2 (en) 2016-11-29
CA2833592A1 (en) 2012-11-01
MX341348B (en) 2016-08-17
EP2701724A1 (en) 2014-03-05
AR086051A1 (en) 2013-11-13
CN103608029A (en) 2014-02-26
JP2014513089A (en) 2014-05-29
US11033606B2 (en) 2021-06-15
PE20171516A1 (en) 2017-10-20
IL228947A0 (en) 2013-12-31
EP2701724B1 (en) 2017-05-24
AU2012247530A1 (en) 2013-05-02
JO3283B1 (en) 2018-09-16
IL257179A (en) 2018-03-29
US20140051642A1 (en) 2014-02-20
KR20190088568A (en) 2019-07-26
CO6811861A2 (en) 2013-12-16
CY1120382T1 (en) 2019-07-10
ZA201308821B (en) 2015-01-28

Similar Documents

Publication Publication Date Title
AU2012247530B2 (en) Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinocetan (FOLFIRI)
Rudin et al. SKYSCRAPER-02: primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab+ carboplatin+ etoposide with or without tiragolumab in patients with untreated extensive-stage small cell lung cancer
Halle et al. Defining and targeting BRAF mutations in solid tumors
Cadoo et al. Palbociclib: an evidence-based review of its potential in the treatment of breast cancer
Van Cutsem et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen
Yamaue et al. Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS‐PC Study
Ychou et al. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer
Diel et al. The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease
Ascierto et al. Melanoma
Hu et al. Trop2-targeted therapy in breast cancer
WO2014006113A1 (en) Method of treating cancer by effective amounts of aflibercept
Pfeiffer et al. Current role of antibody therapy in patients with metastatic colorectal cancer
Giaccone et al. A placebo-controlled phase ii study of ruxolitinib in combination with pemetrexed and cisplatin for first-line treatment of patients with advanced nonsquamous non–small-cell lung cancer and systemic inflammation
Ji et al. A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer (KCSG HN07-01)
Torregrosa et al. FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX‐bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study
Levy et al. Toxicity of concomitant cetuximab and radiotherapy with or without initial taxane‐based induction chemotherapy in locally advanced head and neck cancer
Sideras et al. North central cancer treatment group (NCCTG) N0537: phase II trial of VEGF-trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane
HK1239531A1 (en) Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri)
OA16640A (en) Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinocetan (FOLFIRI).
NZ617573B2 (en) Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri)
HK1189506A (en) Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri)
HK1189506B (en) Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri)
Gunturu et al. Highlights on the first line treatment of metastatic pancreatic cancer
Kainickal et al. Targeted therapy in recurrent or metastatic head and neck carcinoma
CA3211742A1 (en) Use of sephb4-hsa fusion protein as a first-line therapy in cancer treatment

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)